Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Rises By 7.1%

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 126,800 shares, an increase of 7.1% from the November 30th total of 118,400 shares. Based on an average daily volume of 37,000 shares, the short-interest ratio is currently 3.4 days. Approximately 2.1% of the company’s stock are sold short.

Aytu BioPharma Stock Up 5.6 %

Shares of Aytu BioPharma stock traded up $0.09 during trading on Wednesday, reaching $1.70. The stock had a trading volume of 33,273 shares, compared to its average volume of 24,032. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $10.45 million, a price-to-earnings ratio of -1.38 and a beta of -1.40. Aytu BioPharma has a 52 week low of $1.30 and a 52 week high of $3.45. The stock has a fifty day moving average price of $1.66 and a two-hundred day moving average price of $2.25.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors have recently bought and sold shares of AYTU. Stonepine Capital Management LLC raised its holdings in shares of Aytu BioPharma by 6.0% in the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after purchasing an additional 28,489 shares during the last quarter. Armistice Capital LLC bought a new position in Aytu BioPharma in the second quarter valued at $736,000. Finally, Dimensional Fund Advisors LP lifted its position in Aytu BioPharma by 54.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after buying an additional 8,311 shares in the last quarter. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.